• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Global Urological Cancer Market Forecast to 2022 - Key Players are Novartis, Pfizer & AstraZeneca - Research and Markets

    Global Urological Cancer Market Forecast to 2022 - Key Players are Novartis, Pfizer & AstraZeneca - Research and Markets

  2. Medullary Thyroid Cancer Pipeline Review, H2 2016 - Companies & Molecules by Phase III, Phase II & Pre-Clinical Stage - Research and Markets

    Medullary Thyroid Cancer Pipeline Review, H2 2016 - Companies & Molecules by Phase III, Phase II & Pre-Clinical Stage - Research and Markets

  3. Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

    Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients with Relapsing Multiple Sclerosis Presented at 32nd ECTRIMS

  4. UPDATE: Growth stocks could replace dividend stocks as star performers

    UPDATE: Growth stocks could replace dividend stocks as star performers

  5. UPDATE: 7 cheap growth stocks for double-digit profit gains in 2017

    UPDATE: 7 cheap growth stocks for double-digit profit gains in 2017

  6. Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets

    Relapsing Multiple Sclerosis (RMS) Global Clinical Trials Review, H2, 2016 - Analysis, Technologies & Forecasts - Key Vendors: Biogen, Sanofi, Novartis - Research and Markets

  7. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  8. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  9. Tuttle Tactical Management Weekly Market Notes

    Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...

  10. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.